Beijing Oct. 20 Tian Baoguo, deputy director of the Department of social development and science and technology of the Ministry of science and technology of the Ministry of science and technology, said at a press conference of the joint prevention and control mechanism of the State Council on October 20, China’s four new coronavirus vaccines entering phase III clinical trial stage have so far vaccinated about 60000 subjects, and no serious adverse reactions have been reported. The results of phase III clinical trial are internationally recognized effective indicators to verify vaccine protection. Tian Baoguo introduced that any kind of vaccine, whether in the clinical trial stage, or in the large-scale use stage after marketing, may have adverse reactions. At present, the adverse reactions of the new coronavirus vaccine entering the phase III clinical trial are basically mild adverse reactions, such as local pain and swelling at the vaccination site, as well as transient low fever and fever. Liu Jingzhen, chairman of Sinopharm group, said that the Beijing Institute of biological products and Wuhan Institute of biological products, affiliated to Sinopharm, are currently conducting phase III clinical trials in 10 countries, including the United Arab Emirates, and more than 50000 people have been vaccinated. So far, no serious adverse reactions have been reported. Gao Qiang, general manager of Beijing Kexing zhongweisheng Technology Co., Ltd., said that the company’s partners in Brazil, Indonesia and Turkey have established perfect ADR monitoring system in accordance with the requirements of international common quality management standards for drug clinical trials. So far, some mild adverse reactions have been found, but no serious adverse reactions related to vaccine have been reported from all partners.